Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Patients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead to inappropriate treatment discontinuation.
Manitz et al. 2022 Journal for ImmunoTherapy of Cancer 10: e003302
Therefore, immune response criteria were developed to capture better novel response patterns seen with ICIs.
Manitz et al. 2022 Journal for ImmunoTherapy of Cancer 10: e003302
as a surrogate endpoint for OS in the whole population, immune-related PFS by irRECIST did not show improved predictive value compared with PFS by RECIST 1.1.
Manitz et al. 2022 …